Internal mammary sentinel node biopsy for breast cancer

Eli Avisar, Manuel A. Molina, Michelino Scarlata, Frederick L Moffat

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The purpose of this study was to determine the value of lymphoscintigraphy (LS) for internal mammary sentinel node (IMSN) identification, the metastatic rate, and the change in staging and treatment. Methods: Between 2001 and 2007 a prospective database was obtained of all patients undergoing IMSN biopsies using an open or thoracoscopic approach. Radiotracer injection was peritumoral. Results: Thirty-four patients were included. There was one man. Three had ductal carcinoma in situ. LS showed IMSN in 47.1%. The IMSN biopsy success rate was 91.2%. Seven of the 28 successfully biopsied invasive cancer patients had metastatic IMSNs (25%). Positive IMSNs were associated with positive axillary nodes in 71.4% (P = .036). All patients with positive IMSNs were upstaged and received radiation to the internal mammary chain. In 4 of 28 patients (14%) the chemotherapy plans were probably altered. In univariate and multivariate analyses tumor size, location, nuclear grade, estrogen receptors, progesterone receptors, Her-2, and histology were not significant predictors of positivity. Conclusions: IMSNs were positive in 25% of the invasive cancer patients. All had treatment changes. LS identified less than 50% of IMSNs. There are no good tumor-related predictors of IMSN positivity.

Original languageEnglish
Pages (from-to)490-494
Number of pages5
JournalAmerican Journal of Surgery
Volume196
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Breast
Breast Neoplasms
Lymphoscintigraphy
Biopsy
Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Progesterone Receptors
Estrogen Receptors
cyhalothrin
Histology
Multivariate Analysis
Databases
Radiation
Drug Therapy
Injections
Therapeutics

Keywords

  • Breast neoplasms
  • Internal mammary nodes
  • Lymphoscintigraphy
  • Sentinel node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Internal mammary sentinel node biopsy for breast cancer. / Avisar, Eli; Molina, Manuel A.; Scarlata, Michelino; Moffat, Frederick L.

In: American Journal of Surgery, Vol. 196, No. 4, 01.10.2008, p. 490-494.

Research output: Contribution to journalArticle

Avisar, Eli ; Molina, Manuel A. ; Scarlata, Michelino ; Moffat, Frederick L. / Internal mammary sentinel node biopsy for breast cancer. In: American Journal of Surgery. 2008 ; Vol. 196, No. 4. pp. 490-494.
@article{3c0db36457f84ce488b5de7751061c6a,
title = "Internal mammary sentinel node biopsy for breast cancer",
abstract = "Background: The purpose of this study was to determine the value of lymphoscintigraphy (LS) for internal mammary sentinel node (IMSN) identification, the metastatic rate, and the change in staging and treatment. Methods: Between 2001 and 2007 a prospective database was obtained of all patients undergoing IMSN biopsies using an open or thoracoscopic approach. Radiotracer injection was peritumoral. Results: Thirty-four patients were included. There was one man. Three had ductal carcinoma in situ. LS showed IMSN in 47.1{\%}. The IMSN biopsy success rate was 91.2{\%}. Seven of the 28 successfully biopsied invasive cancer patients had metastatic IMSNs (25{\%}). Positive IMSNs were associated with positive axillary nodes in 71.4{\%} (P = .036). All patients with positive IMSNs were upstaged and received radiation to the internal mammary chain. In 4 of 28 patients (14{\%}) the chemotherapy plans were probably altered. In univariate and multivariate analyses tumor size, location, nuclear grade, estrogen receptors, progesterone receptors, Her-2, and histology were not significant predictors of positivity. Conclusions: IMSNs were positive in 25{\%} of the invasive cancer patients. All had treatment changes. LS identified less than 50{\%} of IMSNs. There are no good tumor-related predictors of IMSN positivity.",
keywords = "Breast neoplasms, Internal mammary nodes, Lymphoscintigraphy, Sentinel node biopsy",
author = "Eli Avisar and Molina, {Manuel A.} and Michelino Scarlata and Moffat, {Frederick L}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.amjsurg.2008.06.003",
language = "English",
volume = "196",
pages = "490--494",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Internal mammary sentinel node biopsy for breast cancer

AU - Avisar, Eli

AU - Molina, Manuel A.

AU - Scarlata, Michelino

AU - Moffat, Frederick L

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background: The purpose of this study was to determine the value of lymphoscintigraphy (LS) for internal mammary sentinel node (IMSN) identification, the metastatic rate, and the change in staging and treatment. Methods: Between 2001 and 2007 a prospective database was obtained of all patients undergoing IMSN biopsies using an open or thoracoscopic approach. Radiotracer injection was peritumoral. Results: Thirty-four patients were included. There was one man. Three had ductal carcinoma in situ. LS showed IMSN in 47.1%. The IMSN biopsy success rate was 91.2%. Seven of the 28 successfully biopsied invasive cancer patients had metastatic IMSNs (25%). Positive IMSNs were associated with positive axillary nodes in 71.4% (P = .036). All patients with positive IMSNs were upstaged and received radiation to the internal mammary chain. In 4 of 28 patients (14%) the chemotherapy plans were probably altered. In univariate and multivariate analyses tumor size, location, nuclear grade, estrogen receptors, progesterone receptors, Her-2, and histology were not significant predictors of positivity. Conclusions: IMSNs were positive in 25% of the invasive cancer patients. All had treatment changes. LS identified less than 50% of IMSNs. There are no good tumor-related predictors of IMSN positivity.

AB - Background: The purpose of this study was to determine the value of lymphoscintigraphy (LS) for internal mammary sentinel node (IMSN) identification, the metastatic rate, and the change in staging and treatment. Methods: Between 2001 and 2007 a prospective database was obtained of all patients undergoing IMSN biopsies using an open or thoracoscopic approach. Radiotracer injection was peritumoral. Results: Thirty-four patients were included. There was one man. Three had ductal carcinoma in situ. LS showed IMSN in 47.1%. The IMSN biopsy success rate was 91.2%. Seven of the 28 successfully biopsied invasive cancer patients had metastatic IMSNs (25%). Positive IMSNs were associated with positive axillary nodes in 71.4% (P = .036). All patients with positive IMSNs were upstaged and received radiation to the internal mammary chain. In 4 of 28 patients (14%) the chemotherapy plans were probably altered. In univariate and multivariate analyses tumor size, location, nuclear grade, estrogen receptors, progesterone receptors, Her-2, and histology were not significant predictors of positivity. Conclusions: IMSNs were positive in 25% of the invasive cancer patients. All had treatment changes. LS identified less than 50% of IMSNs. There are no good tumor-related predictors of IMSN positivity.

KW - Breast neoplasms

KW - Internal mammary nodes

KW - Lymphoscintigraphy

KW - Sentinel node biopsy

UR - http://www.scopus.com/inward/record.url?scp=52049102259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049102259&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2008.06.003

DO - 10.1016/j.amjsurg.2008.06.003

M3 - Article

C2 - 18723148

AN - SCOPUS:52049102259

VL - 196

SP - 490

EP - 494

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -